Healthcare
Cerus Corporation(CERS)
Live Price
Offline$2.70
+5.06% today
1Y Change
+100.00%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $520.00M
- Revenue Growth
- +14.3%
- EPS Growth
- +25.5%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cerus Corporation (CERS) is a Healthcare stock with a market cap of $520.00M and listed on NASDAQ. The stock last traded around $2.70 and up 100.0% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +14.3%, EPS growth of +25.5%, a dividend yield of 0.0%. What stands out right now is revenue +14.3%, EPS +25.5%, free cash flow 0.0% with operating margin -7.9% and ROIC -10.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Stock Foundry combines CERS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+14.3% vs +7.6% peer median
Operating Margin
Below sector median
-7.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +14.3% and EPS at +25.5%, with operating margin around -7.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.0% | -3.8% | +3.8% |
2026 Mar 2, 2026 | +0.0% | -15.8% | -23.7% | -31.6% |
2025 Nov 6, 2025 | +99.5% | +21.3% | +13.5% | +46.8% |
Benchmark Edge
CERS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CERS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CERS Max Drawdown
-38.32%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CERS and SPY.
Company Overview
Cerus Corporation
NASDAQ
Cerus Corporation is a biomedical products company dedicated to enhancing blood transfusion safety through its INTERCEPT Blood System. This platform inactivates a broad range of pathogens, including viruses, bacteria, and parasites, in blood components to reduce the risk of transfusion-transmitted infections. The INTERCEPT system for platelets and plasma holds both CE mark and FDA approval, making it available to blood centers and hospitals globally, including in the United States, Europe, the Commonwealth of Independent States, the Middle East, and select other regions. In the U.S., the INTERCEPT Blood System for Cryoprecipitation produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex, known as INTERCEPT Fibrinogen Complex, a therapeutic for treating bleeding associated with fibrinogen deficiency in settings like trauma, obstetrics, and surgery. The company operates solely in the blood safety segment, supplying these technologies to support safe blood availability for patients. Founded in 1991 and headquartered in Concord, California, Cerus Corporation plays a vital role in transfusion medicine by providing pathogen-protected platelets, plasma, and fibrinogen products.
- Leadership
- Mr. William M. Greenman
- Employees
- 614
- Street Address
- 1220 Concord Avenue, Suite 600
- Mailing
- Concord, CA, 94520
- Region
- Concord, CA, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.3
- Price/Book
- 7.4
Growth
- Revenue
- +14.3%
- EPS
- +25.5%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 54.3%
- Operating Margin
- -7.9%
- Net Margin
- -4.3%
- ROE
- -15.4%
- ROIC
- -10.3%
Balance Sheet
- Debt/Equity
- 1.44
- Current Ratio
- 1.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.